RxDoctor Payments DataLook up a doctor →

Shelby Cochran, APRN

Family · Fayetteville, ARNPI 1700343209

Payments from drug & device makers

$22,991in general payments, 2019–2025

Across 688 payments — averaging $33.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$9K
  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Enterra Medical, Inc.$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$1K
  • plus $6K from 32 others

What the payments were for

  • Consulting fees$1,0805%
  • Speaking & faculty fees$5,40023%
  • Travel & lodging$1,9569%
  • Food & beverage$14,41163%
  • Education$1431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,991 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$38,645
Medicare patients
309
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin26$84,339
LinzessLinaclotide30$24,023
CreonLipase/Protease/Amylase18$13,671
Mesalamine14$12,007
Colestipol Hcl130$9,034
Ursodiol20$5,194
Sucralfate109$2,914
Pantoprazole Sodium205$2,055
Budesonide DrBudesonide14$1,952
Omeprazole237$1,899
Esomeprazole Magnesium36$912
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates13$815
Famotidine51$469
Ondansetron OdtOndansetron39$290
Dicyclomine Hcl25$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,503$84,33926 claims
AbbVieLinzess, Creon$3,373$37,69448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.

Other family in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →